Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

Fintel reports that on September 16, 2024, JP Morgan upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

With a volume of 492,652, the price of BNTX is up 6.46% at $111.78. RSI indicators hint that the underlying stock may be ...

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

Summit Therapeutics (SMMT) boost Instil Bio (TIL) and BioNTech (BNTX) as its PD-1/VEGF bispecific antibody outperforms ...